Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi. 1985 Jun;37(6):888-96.
Cis-dichlorodiammine platinum (CDDP) has recently been introduced for the treatment of human malignancies. CDDP belongs to the group of heavy metals and has nephrotoxicity, whose side effects limit the dose that can be used in patients. The urinary excretion of lactate dehydrogenase (LDH), gamma-glutamyl transpeptidase (gamma-GTP), alkaline phosphatase (ALP), arylamidase (AA) activity and beta 2-microglobulin was determined in ovarian cancer patients receiving sequential combination chemotherapy with CDDP, adriamycin (ADM) and cyclophosphamide (CPA) (PAC chemotherapy) to evaluate the sensitivity of these indices for acute renal tubular damage and compared with the change in serum BUN, Cr and Ccr values. Increases in enzyme excretion after PAC chemotherapy were more often noticed and the urinary enzyme activity varied up to the 10.4-fold of the control, while serum BUN, Cr and Ccr values remained almost within normal limits. Enzyme excretion returned almost to the normal value in one week. A comparison between the urinary enzyme excretion especially AA value and serum BUN, Cr and Ccr values indicated that the serial determination of the urinary AA excretion pattern is more useful in detecting CDDP-induced nephrotoxicity than that of serum BUN, Cr and Ccr values.
顺式二氯二氨铂（CDDP）最近已被用于治疗人类恶性肿瘤。CDDP属于重金属类，具有肾毒性，其副作用限制了可用于患者的剂量。在接受CDDP、阿霉素（ADM）和环磷酰胺（CPA）序贯联合化疗（PAC化疗）的卵巢癌患者中，测定了乳酸脱氢酶（LDH）、γ-谷氨酰转肽酶（γ-GTP）、碱性磷酸酶（ALP）、芳基酰胺酶（AA）活性和β2-微球蛋白的尿排泄情况，以评估这些指标对急性肾小管损伤的敏感性，并与血清尿素氮（BUN）、肌酐（Cr）和肌酐清除率（Ccr）值的变化进行比较。PAC化疗后酶排泄增加的情况更常被注意到，尿酶活性变化高达对照值的10.4倍，而血清BUN、Cr和Ccr值几乎保持在正常范围内。酶排泄在一周内几乎恢复到正常值。尿酶排泄尤其是AA值与血清BUN、Cr和Ccr值之间的比较表明，连续测定尿AA排泄模式在检测CDDP诱导的肾毒性方面比血清BUN、Cr和Ccr值更有用。
